<?xml version="1.0" encoding="UTF-8"?>
<gtr:projectOverview xmlns:gtr="http://gtr.ukri.org/api"><gtr:projectComposition><gtr:collaborations/><gtr:leadResearchOrganisation url="http://gtr.ukri.org:80/organisation/5F8541BB-0A2B-48DA-9D6C-3C4BD4D3FC4E"><gtr:id>5F8541BB-0A2B-48DA-9D6C-3C4BD4D3FC4E</gtr:id><gtr:name>MicroPharm Limited</gtr:name><gtr:address><gtr:line1>Station Road 
Industrial Estate</gtr:line1><gtr:city>Newcastle Emlyn</gtr:city><gtr:postCode>SA38 9BY</gtr:postCode><gtr:region>Wales</gtr:region></gtr:address><gtr:typeInd>P</gtr:typeInd></gtr:leadResearchOrganisation><gtr:organisationRoles><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/5F8541BB-0A2B-48DA-9D6C-3C4BD4D3FC4E" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:type="gtr:organisationParticipantRole"><gtr:id>5F8541BB-0A2B-48DA-9D6C-3C4BD4D3FC4E</gtr:id><gtr:name>MicroPharm Limited</gtr:name><gtr:address><gtr:line1>Station Road 
Industrial Estate</gtr:line1><gtr:city>Newcastle Emlyn</gtr:city><gtr:postCode>SA38 9BY</gtr:postCode><gtr:region>Wales</gtr:region></gtr:address><gtr:roles><gtr:role><gtr:name>PARTICIPANT</gtr:name></gtr:role><gtr:role><gtr:name>LEAD_PARTICIPANT</gtr:name></gtr:role></gtr:roles><gtr:offerGrant>787152.0</gtr:offerGrant><gtr:projectCost>1311920.0</gtr:projectCost></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/83D87776-5958-42AE-889D-B8AECF16B468" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:type="gtr:organisationParticipantRole"><gtr:id>83D87776-5958-42AE-889D-B8AECF16B468</gtr:id><gtr:name>University of Leeds</gtr:name><gtr:address><gtr:line1>University of Leeds</gtr:line1><gtr:line4>Leeds</gtr:line4><gtr:line5>West Yorkshire</gtr:line5><gtr:postCode>LS2 9JT</gtr:postCode><gtr:region>Yorkshire and The Humber</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>PARTICIPANT</gtr:name></gtr:role></gtr:roles><gtr:offerGrant>484095.0</gtr:offerGrant><gtr:projectCost>484095.0</gtr:projectCost></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/7558C1B1-6DF1-4F0A-A0E4-C11C3F3B2FC4" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:type="gtr:organisationParticipantRole"><gtr:id>7558C1B1-6DF1-4F0A-A0E4-C11C3F3B2FC4</gtr:id><gtr:name>Public Health England (Health Protection Agency)</gtr:name><gtr:address><gtr:line1>Public information access office
Public Health England 
Wellington House 
133-155 Waterloo Road</gtr:line1><gtr:city>London</gtr:city><gtr:postCode>SE1 8UG</gtr:postCode><gtr:region>London</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>PARTICIPANT</gtr:name></gtr:role></gtr:roles><gtr:offerGrant>751153.0</gtr:offerGrant><gtr:projectCost>751153.0</gtr:projectCost></gtr:organisationRole></gtr:organisationRoles><gtr:personRoles><gtr:personRole url="http://gtr.ukri.org:80/person/5C53AE29-6004-4069-88BE-DA0469CB567F"><gtr:id>5C53AE29-6004-4069-88BE-DA0469CB567F</gtr:id><gtr:firstName>Ian</gtr:firstName><gtr:surname>Cameron</gtr:surname><gtr:roles><gtr:role><gtr:name>PROJECT_MANAGER</gtr:name></gtr:role></gtr:roles></gtr:personRole></gtr:personRoles><gtr:project url="http://gtr.ukri.org:80/projects?ref=101602"><gtr:id>1F48D5D0-416F-43CE-883E-1A822B9A7288</gtr:id><gtr:title>Use of Ovine Polyclonal Antibodies to Treat Severe Clostridium difficile Infections</gtr:title><gtr:status>Closed</gtr:status><gtr:grantCategory>Collaborative R&amp;D</gtr:grantCategory><gtr:grantReference>101602</gtr:grantReference><gtr:abstractText>One of the commonest causes of hospital acquired infection is the bacterium Clostridium difficile which causes diarrhoea and other effects by releasing two powerful toxins. Such infections far outnumber those due to MRSA and the Centre for Disease Control and Prevention in the USA has noted ?...the incidence of deaths from C.difficile is greater than the extent of deaths from all the other intestinal diseases combined.? The present project involves a novel means of treating patients with severe C. difficile infections by injecting specific antibodies which bind to, and neutralise the toxins. The antibodies are produced by immunising sheep with miniscule amounts of inactivated toxins (similar to the vaccination of infants) and the antibodies are separated from other blood constituents, purified and filled into ampoules ready for intravenous administration as an adjunct to antibiotic therapy.</gtr:abstractText><gtr:fund><gtr:end>2016-10-31</gtr:end><gtr:funder url="http://gtr.ukri.org:80/organisation/E18E2F0F-AC7D-4E02-9559-669F7C8FEC74"><gtr:id>E18E2F0F-AC7D-4E02-9559-669F7C8FEC74</gtr:id><gtr:name>Innovate UK</gtr:name></gtr:funder><gtr:start>2013-11-01</gtr:start><gtr:type>INCOME_ACTUAL</gtr:type><gtr:valuePounds>2022400</gtr:valuePounds></gtr:fund><gtr:output><gtr:artisticAndCreativeProductOutputs/><gtr:collaborationOutputs/><gtr:disseminationOutputs/><gtr:exploitationOutputs/><gtr:furtherFundingOutputs/><gtr:impactSummaryOutputs/><gtr:intellectualPropertyOutputs/><gtr:otherResearchOutputs/><gtr:policyInfluenceOutputs/><gtr:productOutputs/><gtr:researchDatabaseAndModelOutputs/><gtr:researchMaterialOutputs/><gtr:softwareAndTechnicalProductOutputs/><gtr:spinOutOutputs/></gtr:output><gtr:publications/><gtr:identifiers><gtr:identifier type="RCUK">101602</gtr:identifier></gtr:identifiers><gtr:healthCategories/><gtr:researchActivities/><gtr:researchSubjects/><gtr:researchTopics><gtr:researchTopic><gtr:id>D05BC2E0-0345-4A3F-8C3F-775BC42A0819</gtr:id><gtr:text>Unclassified</gtr:text></gtr:researchTopic></gtr:researchTopics><gtr:rcukProgrammes/></gtr:project></gtr:projectComposition></gtr:projectOverview>